Mutations in the breast cancer susceptibility gene 2 (BRCA2) are commonly found in familial pancreatic cancer. Recently, EMSY (11q13.5) has been described as a BRCA2 interacting protein capable of binding and inactivating the protein domain encoded by exon 3 of the BRCA2 gene. Amplification of EMSY occurs in 13% of sporadic breast cancers and is directly linked to increased expression. Here we investigate the amplification status of this new potential oncogene in 59 sporadic pancreatic cancers using fluorescence in situ hybridization (FISH) and tissue microarray (TMA). Real-time quantitative RT-PCR was performed on 20 pancreatic cancer cell lines and overexpression was calculated using the delta-delta-Ct-method. Amplification of EMSY was found in 8/59 cases (13.6%). 9/20 (45%) cell line samples showed overexpression of EMSY. In conclusion, sporadic pancreatic cancer shows amplification of EMSY at prevalence similar to that found in other cancers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2480540 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Poly (ADP-Ribose) Polymerase inhibitors (PARPi) therapy response in an acral melanoma patient with EMSY gene amplification.
JAAD Case Rep
June 2024
Division of Medical Oncology, Department of Medicine, Washington University in Saint Louis, Saint Louis, Missouri.
Prognostic difficulties of men with breast cancer.
Breast J
December 2021
Professor of Surgical Oncology, Research Oncology, Guy's Hospital, London, UK.
Most adequately powered studies confirm a worse prognosis for males versus matched females with breast cancer. There is in-stage migration for stage I cancers with a different ratio of tumor/normal breast tissue in males. Younger men have a better prognosis, largely the result of increased morbidity in the elderly, exacerbated by smoking, low socioeconomic differences, and ethnic disparity.
View Article and Find Full Text PDFExtraneural Metastases of Diffuse Midline Glioma, H3 K27M-Mutant at Diagnosis: Case Report, Review of the Literature, and Identifying Targetable Alterations.
J Pediatr Hematol Oncol
March 2022
Department of Pathology, Upstate Medical University, Syracuse, NY.
Article Synopsis
- - Extraneural metastases are uncommon in pediatric high-grade gliomas, and there is limited knowledge about the genetic characteristics of tumors that spread beyond the central nervous system.
- - A case is presented of a child with a specific type of brain tumor (H3 K27M-mutant diffuse midline glioma) that had spread to the spine and bones at the time of diagnosis, with possible lung metastasis.
- - Key genomic alterations were found, including mutations in H3F3A and TP53, along with amplifications in MET, CDK6, EMSY, and PIK3CG, highlighting the need for sequencing to better understand and target therapies for these metastases.
Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
Cancer Med
May 2021
Department of Pathology and Laboratory Medicine, The Ottawa Hospital, Ottawa, ON, Canada.
Background: In high grade serous ovarian cancer (HGSOC), there is a spectrum of sensitivity to first line platinum-based chemotherapy. This study molecularly characterizes HGSOC patients from two distinct groups of chemotherapy responders (good vs. poor).
View Article and Find Full Text PDFClarifying the role of EMSY in DNA repair in ovarian cancer.
Cancer
August 2019
Cancer Biology and Stem Cells Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!